E. M. Dijkgraaf

A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer

E. M. Dijkgraaf, Saskia J. Santegoets, A.K.L. Reyners et al. · Annals of Oncology · 2015 · 193 citations

Medicine, Oncology, Pharmacology +14

The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival

Saskia J. Santegoets, Anne F. de Groot, E. M. Dijkgraaf et al. · OncoImmunology · 2018 · 42 citations · Full text

Medicine, Hematology, Oncology +17

Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer

E. M. Dijkgraaf, Harry Hollema, MJP Welters et al. · OncoImmunology · 2014 · 32 citations · Full text

Medicine, Immunology, Oncology +17

Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)

S de Groot, Laura G.M. Janssen, Ayoub Charehbili et al. · Breast Cancer Research and Treatment · 2015 · 27 citations · Full text

Medicine, Oncology, Pharmacology +15